X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs MERCK LTD - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD MERCK LTD LUPIN LTD/
MERCK LTD
 
P/E (TTM) x 23.6 34.1 69.2% View Chart
P/BV x 3.2 3.8 83.8% View Chart
Dividend Yield % 0.8 0.7 105.8%  

Financials

 LUPIN LTD   MERCK LTD
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
MERCK LTD
Dec-16
LUPIN LTD/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs1,7501,060 165.1%   
Low Rs1,384623 222.1%   
Sales per share (Unadj.) Rs387.4632.4 61.3%  
Earnings per share (Unadj.) Rs56.645.7 123.9%  
Cash flow per share (Unadj.) Rs76.862.3 123.3%  
Dividends per share (Unadj.) Rs7.5011.00 68.2%  
Dividend yield (eoy) %0.51.3 36.6%  
Book value per share (Unadj.) Rs298.9388.8 76.9%  
Shares outstanding (eoy) m451.5816.60 2,720.4%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x4.01.3 303.9%   
Avg P/E ratio x27.718.4 150.3%  
P/CF ratio (eoy) x20.413.5 151.0%  
Price / Book Value ratio x5.22.2 242.2%  
Dividend payout %13.224.1 55.0%   
Avg Mkt Cap Rs m707,51313,969 5,064.9%   
No. of employees `00016.81.6 1,060.8%   
Total wages/salary Rs m28,4951,487 1,916.7%   
Avg. sales/employee Rs Th10,418.36,631.9 157.1%   
Avg. wages/employee Rs Th1,697.0939.2 180.7%   
Avg. net profit/employee Rs Th1,523.0479.4 317.7%   
INCOME DATA
Net Sales Rs m174,94310,498 1,666.4%  
Other income Rs m1,065242 439.4%   
Total revenues Rs m176,00810,741 1,638.7%   
Gross profit Rs m44,9311,135 3,957.7%  
Depreciation Rs m9,122276 3,311.2%   
Interest Rs m1,5250-   
Profit before tax Rs m35,3491,102 3,207.1%   
Minority Interest Rs m-720-   
Prior Period Items Rs m830-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m9,785343 2,850.3%   
Profit after tax Rs m25,575759 3,370.0%  
Gross profit margin %25.710.8 237.5%  
Effective tax rate %27.731.1 88.9%   
Net profit margin %14.67.2 202.2%  
BALANCE SHEET DATA
Current assets Rs m119,5426,410 1,865.1%   
Current liabilities Rs m61,2068,828 693.3%   
Net working cap to sales %33.3-23.0 -144.7%  
Current ratio x2.00.7 269.0%  
Inventory Days Days7658 131.8%  
Debtors Days Days9038 234.1%  
Net fixed assets Rs m131,6601,406 9,361.5%   
Share capital Rs m903166 544.1%   
"Free" reserves Rs m134,0736,286 2,132.9%   
Net worth Rs m134,9766,455 2,091.2%   
Long term debt Rs m56,4780-   
Total assets Rs m266,0738,828 3,013.9%  
Interest coverage x24.2NM-  
Debt to equity ratio x0.40-  
Sales to assets ratio x0.71.2 55.3%   
Return on assets %10.28.6 118.5%  
Return on equity %18.911.8 161.2%  
Return on capital %19.317.1 112.8%  
Exports to sales %08.3 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs mNA2,209 0.0%   
Fx inflow Rs m81,885959 8,540.3%   
Fx outflow Rs m21,5062,612 823.4%   
Net fx Rs m60,378-1,653 -3,652.2%   
CASH FLOW
From Operations Rs m41,1481,070 3,844.1%  
From Investments Rs m-25,287-750 3,372.9%  
From Financial Activity Rs m4,332-150 -2,891.7%  
Net Cashflow Rs m20,193171 11,815.4%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 51.8 0.4%  
Indian inst/Mut Fund % 11.3 18.2 62.1%  
FIIs % 31.9 1.0 3,190.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 29.1 34.7%  
Shareholders   98,259 28,591 343.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  NOVARTIS  PANACEA BIOTECH  

Compare LUPIN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Idea Plunges 5% on Weak Q3 Peformance(Closing)

Indian share markets finished on a flat note after a five-session record-setting spree as profit booking was witnessed in metal stocks, capital goods stocks.

Related Views on News

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Jan 24, 2018 03:33 PM

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD 8-QTR ANALYSIS

COMPARE LUPIN LTD WITH

MARKET STATS